Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans

J Antimicrob Chemother. 2003 Jun;51(6):1427-9. doi: 10.1093/jac/dkg230. Epub 2003 Apr 25.

Abstract

The activity of caspofungin (CFG) combined with amphotericin B (AMB) against azole-resistant Candida albicans was evaluated in vitro (chequerboard) and in vivo (murine). CFG+AMB resulted in positive interactive effects in vitro (fractional inhibitory concentration index 0.75). Compared with untreated controls, CFG+AMB prolonged mouse survival (P = 0.006) and compared with AMB alone, CFG+AMB prolonged mouse survival (P = 0.36); however, the latter difference was not significant. CFG+AMB treatment significantly reduced kidney cfu compared with untreated controls and CFG-treated groups (P < or = 0.05 for both comparisons). In addition, this combination reduced brain cfu significantly compared with untreated controls and AMB-treated mice (P = 0.005 and 0.05, respectively).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amphotericin B / administration & dosage*
  • Animals
  • Azoles / administration & dosage
  • Azoles / pharmacology*
  • Candida albicans / drug effects*
  • Candida albicans / growth & development
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Caspofungin
  • Drug Resistance, Fungal* / drug effects
  • Drug Resistance, Fungal* / physiology
  • Drug Therapy, Combination
  • Echinocandins
  • Humans
  • Lipopeptides
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Peptides / administration & dosage*
  • Peptides, Cyclic*

Substances

  • Azoles
  • Echinocandins
  • Lipopeptides
  • Peptides
  • Peptides, Cyclic
  • Amphotericin B
  • Caspofungin